## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.99 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($1018.27)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)**
- Source: Insider Monkey | 20251221T180815 | Bullish | Relevance: 100%
- Eli Lilly and Company (LLY) announced updated results from its Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for advanced or metastatic breast cancer, showing continued clinical benefits. The company also revealed plans to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama, to produce synthetic and peptide medicines, including forforglipron. Eli Lilly is recognized as a strong investment, though the article suggests even greater potential in certain AI stocks.

**2. Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)**
- Source: Yahoo Finance | 20251221T154727 | Bullish | Relevance: 100%
- Eli Lilly and Company released updated Phase 3 EMBER-3 study results for Inluriyo (imlunestrant), an oral estrogen receptor antagonist, showing continued clinical benefits for patients with ER+, HER2- advanced or metastatic breast cancer. The data supports Inluriyo's role both as monotherapy and in combination with abemaciclib, demonstrating durable benefits regardless of ESR1 mutation status. The company also announced plans for a new $6 billion manufacturing facility in Huntsville, Alabama, which will produce small molecule synthetic and peptide medicines, including orforglipron for obesity.

**3. ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In â€” News, Forecasts and Outlook (Dec. 22, 2025)**
- Source: ts2.tech | 20251222T120959 | Somewhat-Bullish | Relevance: 75%
- ABIVAX (ABVX) stock is surging due to renewed takeover speculation involving Eli Lilly and its addition to the Nasdaq Biotechnology Index. While the Eli Lilly rumors are unconfirmed, the NBI inclusion is official and provides increased visibility and potential passive investment flows. The long-term outlook for ABIVAX hinges on its lead clinical program, obefazimod, in late-stage development for ulcerative colitis, with Phase 3 maintenance results and Phase 2b Crohn's disease results expected in 2026.

**4. CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer**
- Source: Benzinga | 20251222T181013 | Somewhat-Bullish | Relevance: 74%
- CRISPR Therapeutics provided an update on zugocaptagene geleucel (zugo-cel), an investigational allogeneic CAR T therapy. The therapy showed a 90% overall response rate and 70% complete response rate in patients with relapsed/refractory large B-cell lymphoma (LBCL), with encouraging preliminary data also seen in autoimmune rheumatologic diseases. The company is collaborating with Eli Lilly and Co. to further develop zugo-cel in aggressive B-cell lymphomas.

**5. Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)**
- Source: Finviz | 20251222T120922 | Somewhat-Bullish | Relevance: 74%
- H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating on Viking Therapeutics (VKTX) with a price target of $102, representing almost 190% upside. This positive outlook is driven by successful Phase 3 study outcomes from a competitor, validating Viking's oral obesity program and increasing investor interest. The company specializes in therapies for metabolic and endocrine disorders, focusing on small-molecule drugs for obesity, fatty liver, and diabetes.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.49M) |
| Sells | 28 ($18559.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $18559M sold (28 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.99 indicates undervaluation relative to growth. Forward P/E 33.1x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (4 raises, avg +12%). Insider selling cluster ($18559.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $965.0B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.99 |
| Forward P/E | 33.1 |
| Current P/E | 45.5 |
| YoY Growth | 37.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 1.3% to 2.4% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.6pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.91), momentum weakening. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.37% (CS: 69) | Neutral |
| RSI_14 | 64.7 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.120x | Above |
| vs SMA200 | 1.314x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1076.15
- **Stop Loss:** $1018.27 (5.4% risk)
- **Target:** $1191.91 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $21,523.00
- **Portfolio %:** 21.52%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*